A phase I dose escalation and pharmacokinetic study of oral clofarabine administered daily for 5 days in adult patients with refractory solid tumors.
Phase of Trial: Phase I
Latest Information Update: 24 Aug 2013
At a glance
- Drugs Clofarabine (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 17 Sep 2008 Actual patient number (24) added as reported by ClinicalTrials.gov.
- 17 Sep 2008 Actual end date (Feb 2006) added as reported by ClinicalTrials.gov.
- 22 Feb 2006 Trial identifier CLO152A2 changed to CLO152 reported by ClinicalTrials.gov